Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01983033
Other study ID # 2013/708
Secondary ID B670201318392
Status Completed
Phase N/A
First received November 6, 2013
Last updated May 23, 2017
Start date October 2013
Est. completion date December 2016

Study information

Verified date May 2017
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repetitive negative thinking (RNT) plays an important role in different psychiatric disorders, such as depressive and anxiety disorders, complicated grief, posttraumatic stress disorders, anorexia nervosa. RNT is seen as a vulnerability factor in the onset, duration, severity and relapse of those disorders. Although there is a lot of theoretical research, it is unknown if a group training protocol addressing RNT has an additional effect on Treatment as Usual (TAU) of patients with GAD or Depressive disorder. Our hypothesis is that a training intervention will show a significant effect on declined RNT activity (measured by PSWQ and LARRS), reduced identification with worrying/rumination (measured by CFQ-13 and a Visual Analogue Scale), and reduced scores on metacognitions questionnaire (MCV Dutch version of the MCQ), when compared to TAU (medication, psychotherapy or a combination of both treatments). Further we expect that this effect on RNT will not be temporary and the beneficial effects will remain present over a longer time (9 months). Our third hypothesis claims that reduced RNT will have an effect on Quality of Life, self-esteem and depressive and anxiety scores (measured respectively by WHO-QoL, Rosenberg Self Esteem Questionnaire, BDI-II and STAI; all of them in Dutch version). Fourth hypothesis concerns the effect of the training in the functioning on a neurobiological level. Here we expect that the beneficial effects of training on RNT will increase top-down prefrontal (dorsolateral) cortical control over an overactive bottom-up limbic system. To examine these neurobiological effects, we apply a multimodal approach where we combine resting state fMRI, structural MRI such as diffuse tensor imaging (DTI), anterior spin labelling (ASL). Further, in our department we developed an audio critique task where participants hear different kinds of critique amongst some of negative valence which will be especially problematic for ruminative patients reflecting difficulties and differences these top-down/bottom-up processes when compared to a healthy control group at baseline. Further, we hypothesize that only when coping with RNT is successful these neuronal processes will normalize. We do not expect changes in the waiting list group.

To examine these clinical and neuronal effects, people suffering from GAD and/or depression will be allocated by randomisation to an active treatment condition (ATC) and a waiting list control group (WLC). All the participants will be patients treated by general practitioner, psychologist or psychiatrist. Training exists of 8 sessions in group (max 12 participants) on a weekly basis, except for the last session, which takes place after one month). During the training people will get information on RNT, they will be trained in re-allocation of their attention, will receive some basic ideas about becoming aware of dysfunctional thinking and learn coping strategies such as stimulus control and engaging in positive activity.

Assessments will take place before and after treatment for the ATC. The WLC will be measured at the start of the WLC and 12 weeks later. Measurement takes place by means of questionnaires and fMRI. During the fMRI, people will undergo a resting state paradigm and some tasks triggering RNT. 3 and 9 months after the group treatment, participants will be evaluated again on RNT by means of questionnaires. Participants in WLC will receive group treatment from the moment the parallel active treatment condition is ended (e.g. after 12 weeks). This group will be evaluated immediately after training and at 3 and 9 months follow-up.

At the end of the training, after the 8th session, two participants per run will be asked to cooperate in a qualitative in-depth interview. We are interested in linking results with the group training with some factors such as quantity of sessions, degree of active participation in between sessions. We are also interested in defining which interventions are perceived as most useful and if there is a link between disorder and the usefulness of some interventions.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- GAD

- depression or depression in remission

Exclusion Criteria:

- other psychiatric pathology than GAD or depression screened by senior psychiatrist by means of MINI and psychiatric anamnesis

- Abuse of alcohol, drugs or medication other than prescribed by GP or psychiatrist

- no consent to participate in measurement (questionnaire or fMRI- for fMRI: except medical contra-indications)

- Insufficient knowledge of the current language (Dutch)

- Acute or chronic suicidality

- Acute psychosis or manic depressive disorder

- Not able to commit for the 8 sessions

Study Design


Intervention

Behavioral:
Drop It training session
8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
treatment as usual
12 weeks of no intervention other than treatment as usual

Locations

Country Name City State
Belgium Ghent University Hospital Ghent

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Ghent University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in repetitive negative thinking degree of repetitive negative thinking (PSWQ Dutch version) at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up
Primary change in repetitive negative thinking degree of repetitive negative thinking (LARRS) at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up
Primary change in repetitive negative thinking changes in metacognitions on RNT (MCV Dutch version of MCQ) at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up
Primary change in repetitive negative thinking degree of identification/disengagement (CFQ-13) at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up
Primary change in repetitive negative thinking degree of identification/disengagement (VAS) at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up
Secondary change in resting state fMRI Structural MRI and DTI fMRI combined with critique paradigm at baseline and at the end of active treatment (12 weeks)
Secondary change in Quality of Life WHO Quality of Life Dutch version two weeks before active treatment,12 weeks after the start of the active treatment, 3 months after follow-up and 9 months after follow-up
Secondary change in self-esteem measured by Rosenberg Self Esteem Questionnaire Dutch version two weeks before active treatment,12 weeks after the start of the active treatment, 3 months after follow-up and 9 months after follow-up
Secondary change in depression and anxiety BDI-II, STAI Dutch versions two weeks before active treatment/waiting list, 12 weeks after active treatment/waiting list, follow-up 3 and 9 months after active treatment
Secondary change in personality features using the TCI (Temperament and Character Inventory) two weeks before active treatment/waiting list, 12 weeks after the start of the active treatment/waiting list
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A